Chlamydia Fusion Proteins for Antigen Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for Chlamydia trachomatis infection are inadequate due to its asymptomatic nature, leading to delayed detection and ineffective treatment, as existing methods rely on predefined or denatured antigens, which are not comprehensive enough to identify relevant antigens for diagnosis and vaccine development.
Innovation Solution
The use of fusion proteins covering the entire genome to identify immunodominant Chlamydia trachomatis antigens, allowing for more accurate determination of relative immunodominance, and the development of compositions comprising isolated proteins such as CT806, CT823, CT841, and pCT03, along with their homologues, for diagnostic and therapeutic applications, including vaccines and adjuvants like CpG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If predefined or denatured antigens are used for diagnosis, then the diagnostic process is simpler, but the accuracy and comprehensiveness of antigen identification is insufficient
Solution Approach 1:
The patent segments the chlamydial genome into multiple fusion proteins (e.g., CT806, CT823, CT841, pCT03) that are individually screened and identified as immunodominant antigens. This segmentation allows comprehensive coverage of the genome while maintaining manageable analysis through systematic division of the antigenic profile into discrete, testable units.
Solution Approach 2:
The patent employs preliminary action by using fusion proteins that cover the entire chlamydial genome before actual diagnosis. These pre-generated fusion proteins serve as a comprehensive antigen panel that can be used to screen patient samples, eliminating the need for de novo antigen identification during the diagnostic process and thereby improving accuracy without increasing operational complexity.
2Measurement precision
If fusion proteins covering the entire genome are used to identify immunodominant antigens, then the comprehensiveness and accuracy of antigen identification is improved, but the complexity of the screening process increases
Solution Approach 1:
The fusion proteins designed in this patent serve multiple functions: they act as diagnostic reagents, vaccine candidates, and research tools for understanding chlamydial pathogenesis. By creating a universal panel of fusion proteins that cover the entire genome, the patent enables a single comprehensive system to address multiple needs in chlamydia research and treatment.
Solution Approach 2:
The patent changes the parameter of antigen presentation by using fusion proteins with specific immunodominant characteristics. These fusion proteins are engineered to express chlamydial antigens in a conformation that optimizes their immunogenicity and recognizability by host antibodies, thereby improving the precision of immunodominance determination while maintaining manageable system complexity through controlled protein design.
3Reliability
If comprehensive antigen screening is performed to identify pathogenesis-related antigens, then the effectiveness of treatment and vaccine development is improved, but the time required for analysis increases
Solution Approach 1:
The patent performs preliminary action by pre-identifying and characterizing immunodominant antigens through fusion protein screening before actual clinical diagnosis. The fusion proteins are prepared and characterized in advance, creating a ready-to-use diagnostic panel that can rapidly test patient samples without requiring time-consuming antigen identification during the diagnostic process, thus reducing analysis time while maintaining comprehensive coverage for effective treatment guidance.
Data Source
AI summary
The present invention provides Chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.